In North America and Europe, our impact is achieved through targeting health areas in deep need of investment. We measure women, children and adolescent users reached.
From research through to venture funding and post-acquisition, women’s, children’s and adolescents’ health innovations have historically received only a fraction of investment capital compared to those focused on men’s health. Furthermore, due to historical restrictions on women taking part in clinical studies during their childbearing years, studies have been heavily weighted towards adult male patients which has led to a male centric health system. Clinical trials on children are also rare, often leaving medical professionals with no option but to use medicines off-label and to rely on poorly tailored medical devices and diagnostic tests to test and treat children. As a result, health inequalities persist between men and women and between men and children. These are further compounded when considering other aspects of diversity such as the socioeconomic determinants of health and racism and further multiplied when considering health outcomes in low and middle income countries (LMICs) relative to wealthier countries, especially those in sub-Saharan Africa.
We believe technology can play an important role in filling the gap of access to high quality health care globally (inclusive of LMICs) and that impact investors hold the key to making this possible. Change is needed to break the cycle of decades of waiting time before accessing the newest most promising technologies at an affordable price. We measure women, children and adolescent users reached, as well as lives improved and lives saved, each a subset of the other.
To achieve impact, we invest in companies that have CEOs with an innate desire to scale their solutions globally and that are commercializing resilient technologies designed to reach millions of people worldwide profitably. All the companies we invest in will have growth objectives in LMICs, tied to impact targets, in parallel to a growth strategy in North American and European markets. Our role is to be a key connector and enabler for our companies so that we may unlock their ambitions for inclusive global growth.
As part of our investment processes, we also consider all aspects of gender and racial diversity and report these metrics alongside the impact performance of our portfolios of investments to our investors.
To achieve our mission, we are collaborating with Grand Challenge Canada, an innovation platform that has funded health innovations in over 100 countries over the past decade.
Through this collaboration, we have built a broad global network of medical professionals, health technology experts, donors, funders and impact experts that are available to work with our portfolio companies. We have built relationships with partners on the ground who can be users of cutting-edge health technology solutions in multiple markets from governments to NGOs to private sector operators.
Our firm manages investment vehicles that comply with the European Union’s Sustainable Finance Disclosure Regulation, Article 9.
CBIV provides a Grievance Mechanism for anyone, including individuals, communities, companies, or organizations, who feel negatively affected by CBIV, the Women’s and Children’s Health Technology Fund EU SCSp/Canada Fund LP and related funds, a portfolio company, or any related parties associated with the funds to express their concerns on the linked form. We endeavour to respond quickly in a transparent and fair manner.
Cross-Border Impact Ventures
661 University Avenue, MaRs Centre, West Tower, Suite 1720, Toronto, ON M5G 1M1